Caribou Biosciences Inc. Common Stock (CRBU)
Stock · NASDAQ · Health Care
$0.47as of 10/16/2026
Price chart
Active signals
CRBU Signal Track Record
How signals performed across all stocks →What CRBU's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -5.6% | 34% | October 6, 2026 |
| Bollinger Band Breakout | 22 | +1.6% | 50% | July 7, 2026 |
| Bollinger Band Breakdown | 18 | -6.2% | 28% | October 6, 2026 |
| 200-Day Moving Average TouchActive now | 16 | +1.3% | 50% | July 7, 2026 |
| Any 20-session window (baseline) | -6.0% | 38% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CRBU
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 97
- Website
- www.cariboubio.com/
Fundamentals
- 1-day range
- $0.4491$0.4781
- Market cap
- $162.66M
- P/E (trailing)
- —
- P/E (forward)
- -0.52
- EPS (trailing)
- $-1.08
- Dividend yield
- —
- Beta
- 2.45
- Avg. volume
- 2.38M
How Caribou Biosciences Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 5, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Caribou Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CRBUCaribou Biosciences Inc. Common Stock$0.47▲ 1.08%Market cap $162.66MP/E —$0.4425$3.54
- MOLNMolecular Partners AG American Depositary Shares$3.56▼ 2.47%Market cap $163.47MP/E —$2.66$3.96
- LENZLENZ Therapeutics Inc. Common Stock$3.27▼ 8.40%Market cap $163.67MP/E —$3.35$42.98
- ABOSAcumen Pharmaceuticals Inc. Common Stock$1.69▲ 1.20%Market cap $164.68MP/E —$1.5$3.6
- IPHAInnate Pharma S.A. ADS$1.43▼ 3.38%Market cap $167.42MP/E —$1.03$2.33
- HUMAHumacyte Inc. Common Stock$0.429▼ 2.50%Market cap $157.54MP/E —$0.337$1.9
- TNYATenaya Therapeutics Inc. Common Stock$0.381▼ 6.62%Market cap $157.50MP/E —$0.3601$2.04
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CRBU Caribou Biosciences Inc. Common Stock | $162.66M | — | $0.47 | ▲ 1.08% | $0.4425$3.54 |
| MOLN Molecular Partners AG American Depositary Shares | $163.47M | — | $3.56 | ▼ 2.47% | $2.66$3.96 |
| LENZ LENZ Therapeutics Inc. Common Stock | $163.67M | — | $3.27 | ▼ 8.40% | $3.35$42.98 |
| ABOS Acumen Pharmaceuticals Inc. Common Stock | $164.68M | — | $1.69 | ▲ 1.20% | $1.5$3.6 |
| IPHA Innate Pharma S.A. ADS | $167.42M | — | $1.43 | ▼ 3.38% | $1.03$2.33 |
| HUMA Humacyte Inc. Common Stock | $157.54M | — | $0.429 | ▼ 2.50% | $0.337$1.9 |
| TNYA Tenaya Therapeutics Inc. Common Stock | $157.50M | — | $0.381 | ▼ 6.62% | $0.3601$2.04 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen BankruptcyBenzinga · 10/9/2026
- This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For FridayBenzinga · 10/9/2026
- In the hunt for reverse merger targets, Caribou could be prized gameYahoo · 10/8/2026
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga · 10/8/2026
- This Tyler Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursdaybenzinga · 10/8/2026
- This Tyler Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For ThursdayBenzinga · 10/8/2026
- Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market SessionBenzinga · 10/8/2026
- HC Wainwright & Co. Downgrades Caribou Biosciences to NeutralBenzinga · 10/8/2026
- Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.ChartMill · 10/7/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 37.71M
- Total value held
- $67.17M
- Institutional holders
- 131
- Unknown4.69M
- Unknown3.77M
- Unknown2.59M
- Unknown2.50M
- Unknown2.14M
- Unknown1.76M
- Unknown1.30M
- Unknown1.21M
- Unknown1.21M
- Unknown1.07M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
No recent news for Caribou Biosciences (CRBU)
There are no recent news releases specifically about Caribou Biosciences in the past week. The stock remains unchanged in terms of public announcements. Technical indicators show RSI at 35.1 and support around $1.59, but without new information the market context is limited.
No recent news for Caribou Biosciences (CRBU). There are no recent news releases specifically about Caribou Biosciences in the past week. The stock remains unchanged in terms of public announcements. Technical indicators show RSI at 35.1 and support around $1.59, but without new information the market context is limited.